

A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer

Status: Recruiting

Eligibility Criteria

Sex: Male

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- diagnosis of metastatic castration-resistant prostate cancer (mCRPC): Disease is metastatic either to bone, any lymph node, or both without clear evidence of metastasis to visceral organs - PSA greater than or equal to (\geq) 2 nanogram per milliliter (ng/mL) - at least able to walk and so all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours - see link to clinicaltrials.gov for complete Inclusion criteria

Exclusion Criteria:

- blood clot in the last month - active autoimmune disease within the past 12 months that requires systemic immunosuppressive medications - significant lung disease - another cancer - heart disease in the past six months - see link to clinicaltrials.gov for complete Exclusion criteria

Conditions & Interventions

Interventions:

Drug: Best Supportive Care (BSC), Biological: Pasritamig, Other: Placebo

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), mCRPC, metastatic castration-resistant prostate cancer

More Information

Description: The purpose of this study is to understand if a new treatment (pasritamig) added to best supportive care (including radiation, steroids, pain medication, or medications to strengthen your bones) for metastatic castration-resistant prostate cancer will work better than the best supportive care alone.

Study Contact: Felicia Lin - lin00808@umn.edu

Principal Investigator: Nicholas Zorko

Phase: PHASE3

IRB Number: STUDY00026133

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.